PBI-4050

DRUG3 trials

Sponsors

Liminal BioSciences Ltd.

Conditions

Alström SyndromeDiabetesInflammation and FibrosisMetabolic SyndromeType 2 Diabetes Mellitus

Phase 2

Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome

CompletedNCT02739217

Liminal BioSciences Ltd.Diabetes, Inflammation and Fibrosis

Start: 2016-02-22End: 2018-06-04Updated: 2018-08-29

Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

TerminatedNCT03081598

Liminal BioSciences Ltd.Metabolic Syndrome, Type 2 Diabetes Mellitus

Start: 2017-05-29End: 2018-09-06Updated: 2020-12-08

Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

TerminatedNCT03184584

Liminal BioSciences Ltd.Alström Syndrome

Start: 2017-10-09End: 2020-05-08Updated: 2020-11-03

Related Papers

Treatment with PBI-4050 in patients with Alström syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial.

2018-11-2622 citations